Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 12

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O75317

UPID:
UBP12_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 12; Ubiquitin thioesterase 12; Ubiquitin-hydrolyzing enzyme 1; Ubiquitin-specific-processing protease 12

ALTERNATIVE UPACC:
O75317; A8K0X0; Q5VZV3; Q8TC49

BACKGROUND:
The protein Ubiquitin carboxyl-terminal hydrolase 12, also referred to as Ubiquitin thioesterase 12 or Ubiquitin-hydrolyzing enzyme 1, is integral to the deubiquitinating process within cells. Its activity is significantly enhanced through interactions with WDR20 and WDR48, although it does not participate in the deubiquitination of FANCD2. Its role in conjunction with WDR48 suggests a tumor-suppressive function by enhancing the stability of PHLPP1.

THERAPEUTIC SIGNIFICANCE:
The exploration of Ubiquitin carboxyl-terminal hydrolase 12's function offers promising avenues for the development of novel therapeutic interventions, particularly in leveraging its tumor-suppressive effects.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.